Adamax (Ac-MEHFPGPAG-NH2) is a synthetic peptide derivative that is a designer analogue of semax, described as semax modified with the N-terminal and C-terminal modifications found in Peptide 021. It has been identified as a designer drug in border seizures and has been suggested to be classified as a prescription medicine in New Zealand.[1]
References
- ^ “Classification of Unscheduled Peptides. Submission to the Medicines Classification Committee” (PDF). Medsafe. New Zealand Medicines and Medical Devices Safety Authority. June 2025.